ASCO Daily News

Why Are Early-Onset GI Cancers on the Rise?

ASCO Daily News

Show Notes

Dr. Sumanta (Monty) Pal and Dr. Kimmie Ng discuss the disturbing rise of early-onset gastrointestinal cancers, the unique challenges faced by younger patients, and key research that is shedding light on potential drivers of early diagnoses in colorectal cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello, everyone. I'm Dr. Monty Pal, and I'm a medical oncologist and professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. I'm really delighted to welcome you all to the ASCO Daily News Podcast as the show's new host. I'll be bringing you discussions with leaders in the oncology space on a variety of topics. I've been working hard with the ASCO team on picking the ideal topics to bring to you, and I'm really delighted to introduce my first guest, a dear friend, Dr. Kimmie Ng, to discuss this huge problem that we're seeing nowadays of early-onset GI cancers. Dr. Ng is the associate chief of the Division of Gastrointestinal Oncology at the Dana-Farber Cancer Institute, and she's an associate professor of medicine at Harvard Medical School in Boston. She serves as co-director of the Colon and Rectal Cancer Program. She's also the founding director of the Young-Onset Colorectal Cancer Center at Dana-Farber. I'm sure we'll talk a little bit about that today. Just to note, our full disclosures are available in the transcript of this episode. Dr Ng, it's so great to have you on the podcast. Thanks so much for joining us. Dr. Kimmie Ng: Thank you so much for having me. It's great to be here. Dr. Sumanta (Monty) Pal: I'm going to refer to you as Kimmie, if you don't mind, for the rest of the podcast here. Please, we'll go by first names, if you don't mind. Your research has really done so much to help improve our understanding of early-onset GI cancers. You've done a lot of work to increase awareness in this space. I don't think there's a couple of months that passes by when I don't see you on television on Good Morning America or other shows really broadcasting this really critical message. I think there's a certain sensitivity that we all have to this issue, right? I mean, because receiving a cancer diagnosis at any age is very challenging, but I'm sure that young patients who face a colorectal cancer diagnosis have some very unique challenges. Could you give us a sense of some of those? Dr. Kimmie Ng: I think the other reason why so many people are interested in this and feel touched by this is that it's not just gastrointestinal cancers that are increasing in young people, but actually a multitude of different cancers have been rising in young individuals. And while it is difficult at any age to receive a cancer diagnosis, we do all know that young people getting a diagnosis like this do face unique challenges. Studies have shown that over 80% have children under the age of 18 when they are diagnosed with colorectal cancer, for example, under the age of 50. And many experience career and education disruptions. They are in what we call the 'sandwich generation,' where they're not only taking care of young families or starting to think about starting a young family, but they're also taking care of elderly parents. So it's just a very busy stage of life, and to then be facing a usually terminal cancer diagnosis, it is extremely challenging. The other factors that we've seen that seem to be unique or more prevalent in young patients is that there are higher levels of psychosocial distress, depression, and anxiety, and a majority of patients do need medical attention and treatment for those things, whether it's medication treatment or whether it's counseling or support from psychosocial oncologists. And so the other big issue is fertility. We know that so many of the treatments that these young patients receive do permanently and negatively impact fertility. And for a person who is young, who may still be trying to expand their family or again start a family, it is very impo

More from ASCO Daily News

Oct 15, 2026

Dr. Sara Tolaney joins Dr. Monty Pal to discuss optimizing the sequencing and combination of antibody-drug conjugates for metastatic HER2-positive and triple-negative breast cancer, as well as guidelines for managing serious toxicities like ILD and neutropenia. LINK TO FULL TRANSCRIPT

Oct 1, 2026

Myeloma specialists Dr. Marc Braunstein and Dr. Rahul Banerjee join Dr. Monty Pal to discuss recent breakthroughs for patients with multiple myeloma, including expert advice on how to manage side effects and identify the right treatment among a series of novel immuno- and targeted therapies. LINK TO FULL TRANSCRIPT

Sep 10, 2026

Dr. Jedd Wolchok, a pioneer in melanoma research, joins Dr. Monty Pal to break down practice-changing advances in the field, including landmark 10-year CheckMate-067 survival data, safer immunotherapy dosing, and the rise of neoadjuvant treatment. LINK TO FULL TRANSCRIPT

Sep 3, 2026

Dr. Monty Pal and Dr. Petros Grivas discuss the rapidly evolving management of bladder cancer, including key updates in non-muscle-invasive disease, the integration of novel therapies in the advanced setting, and practical strategies for managing toxicities in clinical practice. LINK TO FULL TRANSCRIPT

Aug 20, 2026

In part two of our miniseries on the global translation gap in oncology, host Dr. Monty Pal and Dr. Regina Barragán-Carrillo explore how ASCO26 Plenary breakthroughs can be adapted to clinical practice in Latin America. Together, they address real-world implementation challenges including delayed diagnoses, finite resource allocation, and access to precision diagnostics. LINK TO FULL TRANSCRIPT

See all episodes →